As long as the epidemic doesn't run close to saturation (and given the multiple effective vaccines it likely won't, ever), NPI-induced relative spread advantage

As long as the epidemic doesn't run close to saturation (and given the multiple effective vaccines it likely won't, ever), NPI-induced relative spread advantages of one strain over another don't make a difference unless they are also absolute advantages compared to non-NPI-scenario. And given the strength of pre- and asymptomatic spread of this particular virus, it's almost immune to selective pressure for weaker symptoms anyways (scarcity of PCR and deep connect tracing can cause some pressure).